Trials / Completed
CompletedNCT04183387
Simvastatin in Uveitis
Open-label Randomized Study of Efficacy and Safety of Simvastatin in Uveitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates anti-inflammatory effects and safety of simvastatin in non-infectious uveitis.
Detailed description
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) have been shown to reduce local and systemic inflammation in animal models of various autoimmune disorders including uveitis. In this open-label, randomized study clinical efficacy and tolerability of simvastatin 40 mg/day for 8 weeks is evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Simvastatin 40mg |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2019-12-03
- Last updated
- 2019-12-03
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT04183387. Inclusion in this directory is not an endorsement.